Acute double blind trial of a new anti-anginal drug: molsidomine.
The antianginal activity of Molsidomine, a recently developed compound, was studied in 6 patients with stable angina pectoris who attended 3 trial sessions. On different days the patients received single doses of Molsidomine (M; 2 mg), isosorbide dinitrate (ISDN; 5 mg) or placebo (P), in a double blind cross-over manner. All patients performed exercise tests at time 0 (before medication) and 30, 60, 120, 240 and 360 min after drug intake. Tests were performed on a treadmill using the Bruce protocol; the ECG were recorded on 3 channel equipment and was stored on 2 channel magnetic tape (Holter system). No difference between basal values before treatment and on exercise during placebo were observed. At a similar submaximal workload after M and ISDN there was no significant change in heart rate or pressure-rate product, a decrease in systolic blood pressure, a reduction of ST ischemic response between 30 to 120 min after drug intake, and after M alone, a significant decrease in diastolic blood pressure during the 6 hour period. Molsidomine produced clear inhibition of exercise-evoked ischemic ST changes and a long-lasting effect on diastolic blood pressure.
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000150:complications; D010069:Oxadiazoles / Q000627:therapeutic use*; D010919:Placebos; D013558:Sydnones / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D009025:Morpholines; D010069:Oxadiazoles; D010919:Placebos; D013558:Sydnones